Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance
- 1 March 2005
- journal article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 15 (2), 209-216
- https://doi.org/10.1111/j.1525-1438.2005.15205.x
Abstract
The objective of the analysis was to determine the effectiveness of re-treating patients with ovarian cancer, primary peritoneal cancer, and fallopian tube cancer with carboplatin after being deemed platinum resistant. From a database period January 1, 1996, to December 12, 2002, 34 patients were identified who received nonplatinum agents before resuming treatment with carboplatin. The median age was 65 years, and a median of two nonplatinum chemotherapy (range 1-5) prior to re-treatment with carboplatin was received. The median platinum-free interval from the time platinum was last received to re-treatment with carboplatin was 15.2 months (95% confidence interval [CI] 12.6-17.9; range 6.2-47.0). A median number of four cycles of carboplatin (range 1-11) was received. Two patients (5.9%) achieved partial response, while 21 patients (61.7%) achieved stable disease. The median time to progression for these 23 patients after re-treatment with carboplatin was 5.7 months (95% CI 5.2-6.3; range 1.8-15.3). Twenty-seven patients have died, and all patients have progressed. Seven patients are still receiving salvage therapy. The median overall survival from the time deemed to be platinum resistant is 23.2 months (95% CI 20.1-26.4). Patients who have been deemed platinum resistant may still benefit from platinum re-treatment after an interval of treatment with nonplatinum agents.Keywords
This publication has 12 references indexed in Scilit:
- Sialometrical and Sialochemical Analysis of Patients with Chronic Graft-Versus-Host Disease—A Prolonged StudyCancer Investigation, 2003
- Why Study Third-, Fourth-, Fifth-,…Line Chemotherapy of Ovarian Cancer?Gynecologic Oncology, 2001
- Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian CancerJournal of Clinical Oncology, 2001
- Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 1998
- “Recurrence within 6 Months of Platinum Therapy”: An Adequate Definition of “Platinum-Refractory” Ovarian Cancer?Gynecologic Oncology, 1998
- Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.Journal of Clinical Oncology, 1995
- Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trialsBritish Journal of Cancer, 1989